Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Poor Outcomes in HIV Negative and HIV Positive Patients with Plasmablastic Lymphoma (PBL) in a Population Based Patient Study

Niamh Appleby, Ruth Cullen, Dan Painter, Alexandra Smith, Eve Roman, Sharon Barrans, PhD, Sheila J.M. O'Connor, Catherine H Burton, Andrew S Jack, Roger G Owen, Reuben M Tooze, PhD FRCP

Blood (2015) 126 (23): 3924.

https://doi.org/10.1182/blood.V126.23.3924.3924

Published: 2015

Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD

Blood (2015) 126 (23): 394.

https://doi.org/10.1182/blood.V126.23.394.394

Published: 2015

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 1981.

https://doi.org/10.1182/blood.V126.23.1981.1981

Published: 2015

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

TP53 Deletion in CLL: The Significance of Borderline Level Deletion

Sheila J.M. O’Connor, PhD, Kathryn R Turner, MSc, Bradley Dickinson, MSc, Sharon L Barrans, PhD, Roger G Owen, Andrew Jack, PhD, MB, Peter Hillmen, MBChB, PhD

Blood (2008) 112 (11): 4178.

https://doi.org/10.1182/blood.V112.11.4178.4178

Published: 2008

Journal Articles

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Andy C Rawstron, BSc, PhD, Darren J Newton, Ruth M. de Tute, Jane Shingles, Fiona L Bennett, Paul A.S. Evans, Sheila J.M. O’Connor, Andrew S Jack, Peter Hillmen

Blood (2008) 112 (11): 2076.

https://doi.org/10.1182/blood.V112.11.2076.2076

Published: 2008

Journal Articles

Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.

Andy C. Rawstron, Fiona L. Bennet, Sheila J.M. O’Connor, Marwan Kwok, James A.L. Fenton, Marieth Plummer, Ruth M. de Tute, Roger G. Owen, Stephen J. Richards, Andrew S. Jack, Peter Hillmen

Blood (2007) 110 (11): 749.

https://doi.org/10.1182/blood.V110.11.749.749

Published: 2007

Journal Articles

Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.

Matthew J. Cullen, MSc, Sharon L. Barrans, PhD, Stephen J. Richards, PhD, Andy C. Rawstron, PhD, Sheila J.M. O’Connor, PhD, Reuben M. Tooze, PhD, Roger G. Owen, MD, Andrew Jack, MD

Blood (2006) 108 (11): 4643.

https://doi.org/10.1182/blood.V108.11.4643.4643

Published: 2006

Journal Articles

Tropical Splenic Lymphoma: Splenic Marginal Zone Lymphoma or Distinct Entity?.

Elizabeth A. Stephens, MBBS, Imelda Bates, MD, George Bedu-Addo, Ivy Ekem, Yvonne Dei, Ohene K. Opare-Sem, Sheila J.M. O’Connor, PhD, Paul A.S. Evans, PhD, Rebecca A. Rollett, BSc, Roger G. Owen, MD

Blood (2006) 108 (11): 4654.

https://doi.org/10.1182/blood.V108.11.4654.4654

Published: 2006

Journal Articles

Rearrangements of MALT1, IgH, FOXP1 , BCL3 and PAX5 Are Rare Events in Extranodal Marginal Zone Lymphoma in the UK.

Sharon L. Barrans, PhD, Kathryn Turner, MSc, Sheila J.M. O’Connor, PhD, Andrew S. Jack, MD, Roger G. Owen, MD

Blood (2006) 108 (11): 4639.

https://doi.org/10.1182/blood.V108.11.4639.4639

Published: 2006

Journal Articles

Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status.

Fiona L. Bennett, BSc, James A.L. Fenton, DPhil, Sheila J.M. O’Connor, PhD, Peter Hillmen, MD, PhD, Andy C. Rawstron, PhD

Blood (2006) 108 (11): 29.

https://doi.org/10.1182/blood.V108.11.29.29

Published: 2006

Journal Articles

Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features.

Fiona L. Bennett, BSc, Andy C. Rawstron, PhD, Sheila J.M. O’Connor, PhD, Paul A.S. Evans, PhD, Peter Hillmen, MD, PhD

Blood (2006) 108 (11): 2815.

https://doi.org/10.1182/blood.V108.11.2815.2815

Published: 2006

Journal Articles

Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.

Roger G. Owen, MD, Im Fan, MSc, Sheila J.M. O’Connor, Phd, Faith E. Davies, MD, Rebecca A. Rollett, BSc, J. Anthony Child, MD, Andy C. Rawstron, Phd

Blood (2006) 108 (11): 5051.

https://doi.org/10.1182/blood.V108.11.5051.5051

Published: 2006

Journal Articles

A Highly Effective Model of Risk Assessment in Diffuse Large B Cell Lymphoma (DLBCL) Using Classification and Regression Tree (CART) Analysis.

Sharon L. Barrans, PhD, Alex Smith, PhD, Sheila J.M. O’Connor, PhD, Kathryn Turner, MSC, Russell Patmore, MD, Roger G. Owen, MD, Eve Roman, PhD, Andrew Jack, MD

Blood (2005) 106 (11): 1918.

https://doi.org/10.1182/blood.V106.11.1918.1918

Published: 2005

NARROW

Poor Outcomes in HIV Negative and HIV Positive Patients with Plasmablastic Lymphoma (PBL) in a Population Based Patient Study

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

TP53 Deletion in CLL: The Significance of Borderline Level Deletion

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.

Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.

Tropical Splenic Lymphoma: Splenic Marginal Zone Lymphoma or Distinct Entity?.

Rearrangements of MALT1, IgH, FOXP1 , BCL3 and PAX5 Are Rare Events in Extranodal Marginal Zone Lymphoma in the UK.

Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status.

Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features.

Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.

A Highly Effective Model of Risk Assessment in Diffuse Large B Cell Lymphoma (DLBCL) Using Classification and Regression Tree (CART) Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only